ANALISIS BIAYA KEMOTERAPI PASIEN KANKER PAYUDARA DAN KANKER SERVIKS DI RSUD ULIN BANJARMASIN

Jurnal Insan Farmasi Indonesia Pub Date : 2020-05-30 DOI:10.36387/jifi.v3i1.500

Noor Aisyah, Akhmad Syarifuddin, Putri Amami, M. Mardiana

{"title":"ANALISIS BIAYA KEMOTERAPI PASIEN KANKER PAYUDARA DAN KANKER SERVIKS DI RSUD ULIN BANJARMASIN","authors":"Noor Aisyah, Akhmad Syarifuddin, Putri Amami, M. Mardiana","doi":"10.36387/jifi.v3i1.500","DOIUrl":null,"url":null,"abstract":"Breast cancer and cervical cancer are the most cancers in Indonesia that require public health action and intervention.Cancer financing at Jamkesmas 2012 ranked second as much Rp.144.7M.The aim of the study was to find out the comparison between the real costs and the INA-CBGs package rates for breast cancer chemotherapy patients and cervical cancer JKN participants in RSUD Ulin Banjarmain.Nonexperimental research method with cross-sectional data design was taken retrospectively from JKN claim file in 2018, the study is comparative.Research samples in cancer patients were 306 episodes of care and 127 episodes of care in cervical cancer patients.Data analysis was tested with one-sample t-test to see the comparison of average real costs with INA CBG rates.Based on the results of one-sample t-test, it shows that in all severity levels(I,II,III) there is a significant difference (p<0.05) between real costs and INA-CBGs package rates, except for the severity of I (class1) values p>0.05. The average cost for breast cancer patients to pay for each chemotherapy, the severity I is Rp.4,496,831 and the severity","PeriodicalId":306551,"journal":{"name":"Jurnal Insan Farmasi Indonesia","volume":"16 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Insan Farmasi Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36387/jifi.v3i1.500","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer and cervical cancer are the most cancers in Indonesia that require public health action and intervention.Cancer financing at Jamkesmas 2012 ranked second as much Rp.144.7M.The aim of the study was to find out the comparison between the real costs and the INA-CBGs package rates for breast cancer chemotherapy patients and cervical cancer JKN participants in RSUD Ulin Banjarmain.Nonexperimental research method with cross-sectional data design was taken retrospectively from JKN claim file in 2018, the study is comparative.Research samples in cancer patients were 306 episodes of care and 127 episodes of care in cervical cancer patients.Data analysis was tested with one-sample t-test to see the comparison of average real costs with INA CBG rates.Based on the results of one-sample t-test, it shows that in all severity levels(I,II,III) there is a significant difference (p<0.05) between real costs and INA-CBGs package rates, except for the severity of I (class1) values p>0.05. The average cost for breast cancer patients to pay for each chemotherapy, the severity I is Rp.4,496,831 and the severity

查看原文本刊更多论文

分析ULIN BANJARMASIN乳腺癌和宫颈癌患者的化疗成本

乳腺癌和宫颈癌是印度尼西亚最需要采取公共卫生行动和干预的癌症。2012年圣诞节的癌症融资排名第二，为1.447亿卢比。本研究的目的是了解乌林班加曼RSUD乳腺癌化疗患者和宫颈癌JKN参与者的实际成本与INA-CBGs一揽子费率的比较。采用非实验研究方法，采用横断面数据设计，对2018年JKN索赔档案进行回顾性分析，进行对比性研究。研究样本为癌症患者306次护理和宫颈癌患者127次护理。数据分析采用单样本t检验，比较平均实际成本与INA CBG率的比较。单样本t检验结果显示，各严重程度(I、II、III)均有显著性差异(p0.05)。乳腺癌患者每次化疗的平均费用，严重程度I为4,496,831，严重程度I为4,496,831

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jurnal Insan Farmasi Indonesia

自引率

0.00%

发文量